Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Tranzyme Halts Gastroparesis Drug Study, Shares Take A Hit

Tranzyme Inc. (TZYM: Quote) Monday said it is discontinuing the second mid-stage trial of its lead drug TZP-102 for treatment of diabetic gastroparesis, due to insufficient efficacy.

Investors were disappointed by the news, as this is the second lead drug that the company has given up this year. Tranzyme shares are currently trading down 22 percent on the Nasdaq.

Gastroparesis, which literally means paralyzed stomach, is a disorder in which the stomach takes too long to empty food into the small intestine. Diabetes is the most common cause of gastroparesis, and it is estimated that about 12 percent of patients with diabetes suffer from gastroparesis worldwide.

The only medication approved by the FDA for treating gastroparesis - Reglan (metoclopramide), carries a black box warning because of the danger of serious side effects like tardive dyskinesia. There is currently a large unmet medical need for the treatment of gastroparesis due to the lack of safe and effective therapies.

Tranzyme, a clinical stage biotechnology company, said the decision was made after the analysis of patients' responsiveness to three daily oral doses of TZP-102 compared to placebo at the end of weeks 4 and 8 of the 12 week trial.

The results are consistent with the findings of a prior Phase 2b trial in that there was a very large placebo effect and no treatment effect, the company said.

In March, Tranzyme's bowel drug candidate - Ulimorelin also disappointed in a phase 3 trial. Ulimorelin was intended to accelerate gastrointestinal recovery in subjects who had undergone partial bowel resection. The company has stopped development and regulatory activities related to Ulimorelin.

Tranzyme currently also has two preclinical drug candidates - TZP-201 for the treatment of various forms of moderate-to-severe diarrhea and TZP-301 for the treatment of obesity and other metabolic diseases.

TZYM is currently trading at $0.60, down $0.14 or 18.92%, on a volume of 0.5 million shares.

Register
To receive FREE breaking news email alerts for Tranzyme Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.